Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver
Sintesi DuoBiz · · 2 min di lettura
Di cosa si tratta
Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics advancing targeted delivery of siRNA therapeutics, today announced a €16 million ($18 million) Seed financing round to expand DELiveri, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types. The round was co-led by 4BIO Capital and IQ Capital, with participation […] The post Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver appeared first on EU-Startups .
Fonte: EU-Startups
